Acurx Pharmaceuticals, Inc. (ACXP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACXP Stock Price Chart Interactive Chart >
ACXP Price/Volume Stats
| Current price | $2.64 | 52-week high | $8.74 |
| Prev. close | $2.65 | 52-week low | $2.59 |
| Day low | $2.64 | Volume | 4,500 |
| Day high | $2.89 | Avg. volume | 23,879 |
| 50-day MA | $3.52 | Dividend yield | N/A |
| 200-day MA | $4.30 | Market Cap | 27.09M |
Acurx Pharmaceuticals, Inc. (ACXP) Company Bio
Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.
Latest ACXP News From Around the Web
Below are the latest news stories about Acurx Pharmaceuticals Inc that investors may wish to consider to help them evaluate ACXP as an investment opportunity.
Maxim Group Thinks Acurx Pharmaceuticals’ Stock is Going to RecoverMaxim Group analyst Jason McCarthy reiterated a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report) yesterday and set a price target of $12.00. The company's shares closed last Tuesday at $4.38, close to its 52-week low of $3.71. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -10.7% and a 21.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. Currently, the analyst consensus on Acurx Pharmaceuticals is a Moderate Buy with an average price target of $12.00. |
Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI)Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the first patient has been enrolled in its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, against the standard of care to treat CDI, vancomycin, in a 64 patient double-blind randomized trial expected to be completed mid-2022. C. difficile bacteria remains o |
Acurx Pharmaceuticals (NASDAQ:ACXP) Coverage Initiated at Maxim GroupMaxim Group started coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP) in a research note issued to investors on Monday morning, The Fly reports. The brokerage issued a buy rating and a $12.00 target price on the stock. Acurx Pharmaceuticals stock opened at $4.22 on Monday. The businesss 50-day simple moving average is $4.91. Acurx Pharmaceuticals [] |
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Buys $24,979.24 in StockAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Director Carl Sailer acquired 5,161 shares of the firm’s stock in a transaction on Tuesday, November 23rd. The stock was purchased at an average price of $4.84 per share, for a total transaction of $24,979.24. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is […] |
David P. Luci Buys 5,200 Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) StockAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) CEO David P. Luci bought 5,200 shares of the firms stock in a transaction that occurred on Friday, November 19th. The shares were purchased at an average cost of $4.80 per share, for a total transaction of $24,960.00. The transaction was disclosed in a legal filing with the SEC, which is [] |
ACXP Price Returns
| 1-mo | -34.00% |
| 3-mo | N/A |
| 6-mo | -43.35% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -38.91% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...